Marshall Wace LLP Decreases Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Marshall Wace LLP lessened its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 50.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 631,628 shares of the biopharmaceutical company's stock after selling 631,657 shares during the period. Marshall Wace LLP owned about 1.11% of Agios Pharmaceuticals worth $20,755,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Venturi Wealth Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth about $33,000. Wingate Wealth Advisors Inc. purchased a new stake in Agios Pharmaceuticals in the fourth quarter worth about $53,000. Sterling Capital Management LLC grew its stake in Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 1,587 shares during the period. KBC Group NV raised its holdings in Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 611 shares in the last quarter. Finally, AlphaQuest LLC lifted its position in Agios Pharmaceuticals by 106.2% during the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after acquiring an additional 2,338 shares during the period.

Insider Buying and Selling

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the transaction, the director now directly owns 149,220 shares of the company's stock, valued at approximately $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.93% of the stock is currently owned by insiders.

Analysts Set New Price Targets

AGIO has been the subject of a number of analyst reports. StockNews.com lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $56.57.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO traded up $0.89 during midday trading on Thursday, hitting $29.26. 378,770 shares of the company's stock traded hands, compared to its average volume of 705,158. The firm has a fifty day moving average of $30.46 and a 200 day moving average of $38.40. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of 2.58 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.